Europe vs. United States: Compulsory Early Outcome Assessments for New Pharmaceutical Products
McDermott Will & Emery is pleased to present this complimentary webcast that will focus on the compulsory early outcome assessments and subsequent compulsory price negotiations applicable to new pharmaceutical products in Germany under the so-called Neuordnung des Arzneimittelmarktes (AMNOG) regulation.
As pharmaceutical prices in Germany have in the past been the starting point for discounts granted in many other European countries, the AMNOG regulation can affect prices in many European countries. Join our panel for a lively and dynamic discussion of important considerations and factors relevant to the medical device industry.
This webcast is geared toward medical device and pharmaceutical companies, health systems, management boards and management employees within health care organizations. Specifically, this webcast will be of interest for any medical device or pharmaceutical company conducting business in Germany.
The webcast will cover the following:
- Legal overview of the new compulsory early outcome assessment proceedings and subsequent price determination
- Pricing and reimbursement in the United States and Europe
- Legal overview, practice issues and implications on international reference pricing under the German AMNOG regulation
- Practical issues in connection with submitting a dossier under the German AMNOG regulation –compared with submission of technology assessments or payer dossiers in the United States
- Comparison of proceedings before the National Institute for Health and Clinical Excellence in the United Kingdom
Simone Breitkopf, Head of Governmental Affairs and Pricing, Alcon Laboratories Inc. and Paul W. Radensky, Partner, McDermott Will & Emery
Stephan Rau, Partner, McDermott Will & Emery
For more information, please contact McDermott Events.© 2013 McDermott Will & Emery
- California Lists Diisononyl Phthalate (DINP) as a Proposition 65 Carcinogen
- Latin American Region Environmental Report: Brazil Highlights (Volume III 2013)
- U.S. Occupational Safety and Health Administration (OSHA) Proposes to Revise Silica Standards and Extends Comment Period
- FDA’s Warning Letter to 23andMe: Ethical and Legal Issues
- Occupational Safety and Health Administration (OSHA) Proposed Rule for Crystalline Silica
- No Avoiding BPCIA (Biologics Price Competition and Innovation Act) For Biosimilars: No Patent Declaratory Judgment Action Before Biosimilars Application Is Filed
- Energy and Environment Update - November 11, 2013
- Rite Aid to Pay $12.3 Million for Failing to Properly Manage Waste Products from its California Stores